Mine has done this to every house we have lived. So I moved to a house without one. It's been great.
Stock Markets
24,812,936 Views |
233493 Replies |
Last: 15 hrs ago by Quacked
Spoony Love said:
Mine has done this to every house we have lived. So I moved to a house without one. It's been great.
AUSTIN, Texas, July 21, 2021(GLOBE NEWSWIRE) -- Cassava Sciences, Inc.(SAVA), a biotechnology company focused on Alzheimer's disease, today announced it will present two new clinical datasets for its product candidates at the 2021 Alzheimer's Association International Conference(AAIC), which is being held in Denver, Coand virtually on July 26ththrough July 30th. Cassava Sciences' investigational product candidates include simufilam, a drug treatment for Alzheimer's disease, and SavaDx, a biomarker/diagnostic to detect Alzheimer's disease with a simple blood test.
On Monday, July 26th, at approximately 10 am ET, scientists for Cassava Sciences(SAVA)will show a poster presentation at AAIC, titled "SavaDx, a Novel Plasma Biomarker to Detect Alzheimer's Disease, Confirms Mechanism of Action of Simufilam".
On Thursday, July 29th, at approximately 11 am ET, simufilam will be featured in a live podium presentation at AAIC, including a brief Q&A session. This oral presentation will announce results of an interim analysis on safety and cognition for the first 50 patients with Alzheimer's disease to complete 9 months of open-label treatment. Scientists for Cassava Sciences(SAVA)will also present biomarker data analyzed from cerebrospinal fluid (CSF) collected from 25 study subjects at baseline and again after completing 6 months of open-label drug treatment, including:
AAIC policy requires that all materials submitted to AAIC remain embargoed for public broadcast until their officially scheduled date and time of presentation at AAIC.
Cassava Sciences(SAVA)expects to publicly release all AAIC materials contemporaneously with their scheduled date and time of presentation at AAIC. At those times, materials will be posted on the 'Investors' page of the Company's website: https://www.CassavaSciences.com
About SavaDx
SavaDx is Cassava Sciences' investigational diagnostic to detect Alzheimer's disease. The goal of SavaDx is to make the detection of Alzheimer's as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms. SavaDx was substantially funded by a peer-reviewed research grant award from the National Institutes of Health(NIH).
About Simufilam
Simufilam (sim-uh-FILL-am) is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer's pathology, neurodegeneration and neuroinflammation. The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer's Disease. Simufilam is substantially supported by peer-reviewed research grant awards from the National Institutes of Health(NIH).
About Alzheimer's Disease
Alzheimer's disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.1The annual global cost of dementia is now above $1 trillion,according to Alzheimer's Disease International, a charitable organization.
About AAIC2
The Alzheimer's Association International Conference(AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer's disease.
About Cassava Sciences, Inc.(SAVA)
Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences(SAVA)has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.
Simufilam and SavaDx were both developed in-house. Cassava Sciences(SAVA)owns worldwide development and commercial rights to its research programs in Alzheimer's disease, and related technologies, without royalty obligations to any third party.
On Monday, July 26th, at approximately 10 am ET, scientists for Cassava Sciences(SAVA)will show a poster presentation at AAIC, titled "SavaDx, a Novel Plasma Biomarker to Detect Alzheimer's Disease, Confirms Mechanism of Action of Simufilam".
On Thursday, July 29th, at approximately 11 am ET, simufilam will be featured in a live podium presentation at AAIC, including a brief Q&A session. This oral presentation will announce results of an interim analysis on safety and cognition for the first 50 patients with Alzheimer's disease to complete 9 months of open-label treatment. Scientists for Cassava Sciences(SAVA)will also present biomarker data analyzed from cerebrospinal fluid (CSF) collected from 25 study subjects at baseline and again after completing 6 months of open-label drug treatment, including:
- Biomarkers of Alzheimer's disease: amyloid beta42, total tau, P-tau181
- Biomarkers of neurodegeneration: neurogranin, neurofilament light chain (NfL)
- Biomarkers of neuroinflammation: YKL-40, sTREM2 and HMGB1
AAIC policy requires that all materials submitted to AAIC remain embargoed for public broadcast until their officially scheduled date and time of presentation at AAIC.
Cassava Sciences(SAVA)expects to publicly release all AAIC materials contemporaneously with their scheduled date and time of presentation at AAIC. At those times, materials will be posted on the 'Investors' page of the Company's website: https://www.CassavaSciences.com
About SavaDx
SavaDx is Cassava Sciences' investigational diagnostic to detect Alzheimer's disease. The goal of SavaDx is to make the detection of Alzheimer's as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms. SavaDx was substantially funded by a peer-reviewed research grant award from the National Institutes of Health(NIH).
About Simufilam
Simufilam (sim-uh-FILL-am) is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer's pathology, neurodegeneration and neuroinflammation. The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer's Disease. Simufilam is substantially supported by peer-reviewed research grant awards from the National Institutes of Health(NIH).
About Alzheimer's Disease
Alzheimer's disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.1The annual global cost of dementia is now above $1 trillion,according to Alzheimer's Disease International, a charitable organization.
About AAIC2
The Alzheimer's Association International Conference(AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer's disease.
About Cassava Sciences, Inc.(SAVA)
Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences(SAVA)has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.
Simufilam and SavaDx were both developed in-house. Cassava Sciences(SAVA)owns worldwide development and commercial rights to its research programs in Alzheimer's disease, and related technologies, without royalty obligations to any third party.
OutlawAG04 said:
Morning All,
Been a little busy leading up to today but finally game day for our 3rd kid. Trailed out of most of my short term options but hope you guys kill it today!
A little Aggie girl will soon be here and fun fact Stayed in a hotel last night and the room assignment was 1212 whoop! 7/21/21 seems like a pretty lucky birthday! Officially going zone defense haha!
Congrats man! Praying for good health for mama and baby.
So, I went back and relistened to Carter's chapter 8 on Pivots in "Mastering the Trade".$30,000 Millionaire said:I'm going to give this a go. How are you putting in the volume profile? I need a view like this for tactical trades.McInnis 03 said:In TOS there is a study called "Woodies Pivots" and it automatically paints the pivot you want (I use daily).$30,000 Millionaire said:
McInnis - are you painting the pivot and S/R lines yourself or have you found something to do it automatically?
For giggles I added monthly and weekly pivots to the a chart just to see what it'd look like.
Monthlies are black (pivot) and grey (S/R) and weeklies are light green (pivot) and dark green (s/r).....check out boeing and see if you notice consolidation at pivots....
(In the book, he does mention pivot mid points being levels of importance on points that are spread out quiet a bit, I'd think monthly and weeklies most definitely can qualify there.....
Final note: Woodies pivots are not the "classic pivots" of which may have more use.......may be why some of these levels don't hold true on weekly and monthlies
A few screen caps for perusal:
https://imgur.com/a/20zv5fw
That is amazingly accurate.
You don’t trade for money, you trade for freedom.
CrazyRichAggie said:
Wife got pissed at the garage door yesterday and decided to back out with the passenger door open.
goodness! well here's to all of us having a great lotto Friday to cover your garage door repair!
Yeah, continue to hold it. Good things are coming.Harkrider 93 said:
anyone with a new plan of attack on COOP?
Double_Bagger said:
AUSTIN, Texas, July 21, 2021(GLOBE NEWSWIRE) -- Cassava Sciences, Inc.(SAVA), a biotechnology company focused on Alzheimer's disease, today announced it will present two new clinical datasets for its product candidates at the 2021 Alzheimer's Association International Conference(AAIC), which is being held in Denver, Coand virtually on July 26ththrough July 30th. Cassava Sciences' investigational product candidates include simufilam, a drug treatment for Alzheimer's disease, and SavaDx, a biomarker/diagnostic to detect Alzheimer's disease with a simple blood test.
On Monday, July 26th, at approximately 10 am ET, scientists for Cassava Sciences(SAVA)will show a poster presentation at AAIC, titled "SavaDx, a Novel Plasma Biomarker to Detect Alzheimer's Disease, Confirms Mechanism of Action of Simufilam".
On Thursday, July 29th, at approximately 11 am ET, simufilam will be featured in a live podium presentation at AAIC, including a brief Q&A session. This oral presentation will announce results of an interim analysis on safety and cognition for the first 50 patients with Alzheimer's disease to complete 9 months of open-label treatment. Scientists for Cassava Sciences(SAVA)will also present biomarker data analyzed from cerebrospinal fluid (CSF) collected from 25 study subjects at baseline and again after completing 6 months of open-label drug treatment, including:"Cassava Sciences' contributions to AAIC showcase our efforts to develop innovative product candidates for people living with Alzheimer's disease," said Remi Barbier, President and CEO. "We are honored AAIC's scientific committee has invited us to present the latest clinical dataset for simufilam in an oral presentation on Thursday, July 29th."
- Biomarkers of Alzheimer's disease: amyloid beta42, total tau, P-tau181
- Biomarkers of neurodegeneration: neurogranin, neurofilament light chain (NfL)
- Biomarkers of neuroinflammation: YKL-40, sTREM2 and HMGB1
AAIC policy requires that all materials submitted to AAIC remain embargoed for public broadcast until their officially scheduled date and time of presentation at AAIC.
Cassava Sciences(SAVA)expects to publicly release all AAIC materials contemporaneously with their scheduled date and time of presentation at AAIC. At those times, materials will be posted on the 'Investors' page of the Company's website: https://www.CassavaSciences.com
About SavaDx
SavaDx is Cassava Sciences' investigational diagnostic to detect Alzheimer's disease. The goal of SavaDx is to make the detection of Alzheimer's as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms. SavaDx was substantially funded by a peer-reviewed research grant award from the National Institutes of Health(NIH).
About Simufilam
Simufilam (sim-uh-FILL-am) is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer's pathology, neurodegeneration and neuroinflammation. The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer's Disease. Simufilam is substantially supported by peer-reviewed research grant awards from the National Institutes of Health(NIH).
About Alzheimer's Disease
Alzheimer's disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.1The annual global cost of dementia is now above $1 trillion,according to Alzheimer's Disease International, a charitable organization.
About AAIC2
The Alzheimer's Association International Conference(AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer's disease.
About Cassava Sciences, Inc.(SAVA)
Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences(SAVA)has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.
Simufilam and SavaDx were both developed in-house. Cassava Sciences(SAVA)owns worldwide development and commercial rights to its research programs in Alzheimer's disease, and related technologies, without royalty obligations to any third party.
Sweet Jesus. Two presentations next week?
No kidding.
Red Pear Luke (BCS)
Joined:
May 20, 2021
Posts:
2,200
User Profile
Private Message
How long do you want to ignore this user?
Sponsor
AG
CrazyRichAggie said:
Wife got pissed at the garage door yesterday and decided to back out with the passenger door open.
did she find out about your side gig as a squad member of the FBI (federal bikini investigator)?
Spoony Love said:
Mine has done this to every house we have lived. So I moved to a house without one. It's been great.
Just for clarity. Are you referring to wives or garage doors?
Good question. She's still around. The mailbox is the new victim.
$700 to fix and replace damage parts.
Good choice!
For what its worth it looked like alot more ($) then thatCrazyRichAggie said:
$700 to fix and replace damage parts.
cptthunder said:For what its worth it looked like alot more ($) then thatCrazyRichAggie said:
$700 to fix and replace damage parts.
Yeah, I had $1,500 in my head
Who's the options account on Twitter who posts the Friday lottos?
NM, @ThetaWarrior
NM, @ThetaWarrior
IWM close to bottom of my target zone for exit.
Man. EGOC.
You looking at around 221.70?mazag08 said:
IWM close to bottom of my target zone for exit.
Out on IWM August $222 calls.
Bought when IWM was at $209 on Monday for $1.85 per contract.
Net free yesterday when it hit above $216 at $3.72 per contract.
Profit taken just now at $221.55 at $5.35 per contract.
Now we wait for it to confirm top and buy puts. After the top we have one more leg down to lower lows before the big rip.
Bought when IWM was at $209 on Monday for $1.85 per contract.
Net free yesterday when it hit above $216 at $3.72 per contract.
Profit taken just now at $221.55 at $5.35 per contract.
Now we wait for it to confirm top and buy puts. After the top we have one more leg down to lower lows before the big rip.
Same thing happened to me a few weeks ago. Was $800 for the house call (at night) so that seems right
Come on RIG, you got a looooong way to go brother
SAVA again
Cool. Sold 1/4 of my EGOC at the high to go 2x net free. Let the rest ride.
Am I crazy thinking CLOV is in or nearing a reversal?
Philip J Fry said:
Am I crazy thinking CLOV is in or nearing a reversal?
Sold on the little gap up a few minutes ago. Modest 15%. Didn't want to hold since it's a meme stock and unpredictable
TDA apparently lost my trade price after the AHT reverse split. Anyone had this happen and know what to do?
check a statement.
AG 2000' said:
Man. EGOC.
Apparently, this is one of EGOC subsidiaries now:
I already told myself I am not selling a share of EGOC.tlepoC said:
Cool. Sold 1/4 of my EGOC at the high to go 2x net free. Let the rest ride.
this is my retirement stock...I've got a feeling.
to $10!
Going 7/23 SPY 431P
$SAVA going game six Giannis
Featured Stories
See All
No. 15 A&M's hot start more than enough to run away from NMSU, 38-3
by Olin Buchanan
19:00
10h ago
3.8k
Post Game Review: No. 15 Texas A&M 38, New Mexico State 3
by Kay Naegeli
19:50
1d ago
6.0k
Donors can now earn priority points by giving to Texas Aggies United
by Texas Aggies United
TJM90
What hotel is the the tu football team staying at for our game?
in Billy Liucci's TexAgs Premium
50
Ag with kids
What hotel is the the tu football team staying at for our game?
in Billy Liucci's TexAgs Premium
40